



Bone and Soft Tissue Sarcomas: A “Big” Family of “Rare” Tumors. A Multidisciplinary Targeted Approach and Emerging Topics

Guest Editors:

Dr. Virginia Ferraresi

Department of Medical Oncology
1, IRCCS - “Regina Elena”
National Cancer Institute, 00144
Rome, Italy

Dr. Maria Cecilia Cercato

Epidemiology and Cancer
Registry Unit, IRCCS - “Regina
Elena” National Cancer Institute,
00144 Rome, Italy

Dr. Carmine Zoccali

Department of Oncological
Orthopaedics, IRCCS - “Regina
Elena” National Cancer Institute,
00144 Rome, Italy

Deadline for manuscript
submissions:
closed (31 January 2021)

Message from the Guest Editors

Soft tissue and bone sarcomas are rare malignant tumors globally accounting for less than 1% of all new cancers diagnoses (<0.2% for bone sarcomas) and with an incidence of less than 6 cases/100.000 inhabitants/year (≤ 0.3 cases/100.000/year for bone sarcomas). The problem of the rarity is moreover worsened by fragmentation in over 80 different histological subtypes that often correspond to a different biological behavior and eventually in a different chance of response to chemotherapeutic agents as well as to target therapy and immunotherapy, as shown in recent trials. Sarcomas can affect all the ages of life from childhood to old age and are virtually ubiquitous, often representing a real challenge for surgeons. Management of these patients in reference centers with high level of expertise and within reference networks allowing participation in translational clinical trials is the key to improve the prognosis of these rare tumors.

The aim of this special issue is to underline the value of a multidisciplinary targeted approach and give an overview on emerging topics in specific histotypes.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and
Critical Care Medicine, University
of Tokyo, Tokyo 113-8655, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)